Lantern Pharma Inc. (NASDAQ: LTRN), a US-based clinical stage biopharmaceutical company, announced on Tuesday that it has named Maria L Maccecchini, PhD as a nominee for election to the company's board of directors.

Dr Maccecchini has more than 30 years of biopharmaceutical experience in the development of novel therapies for Alzheimer's, Parkinson's, and other neurodegenerative diseases. She is the founder of Annovis Bio (Nasdaq: ANVS). She has earlier served as the founder and CEO of Symphony Pharmaceuticals/Annovis. She has also served as a partner and director of two angel groups, Robin Hood Ventures and MidAtlantic capital, and as a lecturer at the Wharton Business School. She serves on the boards of organisations that promote entrepreneurship, international trade, and women.

Dr Maccecchini has a PhD in Biochemistry and MSc in Biochemistry and Cell Biology from the University of Basel. She has held two Postdoctoral fellowship positions at the Roche Basel Institute of Technology and at the California Institute of Technology. She has performed research in the labs of Nobel Laureates Susumu Tonegawa, PhD., and Gunter Blobel, M.D., Ph.D., and studied corporate finance at the Wharton Business School.